The Wall Street analysts who cover Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) shares are providing price target projections on the company. They project that the shares will move to $188.1 within the upcoming year. The number they've arrived at is calculated by Zacks.com, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $332 and the lowest is at $60 for the stock.
Analyst Ratings In View
Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)'s shares currently have an ABR of 2.1.
During this fiscal period, Street analysts are projecting $-3.73 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2016-06-30, Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) dialed in an EPS of $-3.14, creating a Surprise Factor of 16.49% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2016-11-14, the date when Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) will release their quarterly results.
In the most recent session, Citigroup Inc. (NYSE:C) shares have traded -0.688%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $0.022 away from the 50-day moving average of $46.883 and $2.255 away from the 200-day moving average of $44.650. From a different angle, the stock has been recently recorded -16.923% off of the 52-week high of 56.460 and +35.878% removed from the 52-week low of 34.520.
Currently, Citigroup, Inc. Common Stock has a price to earnings ratio of 9.927. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 2.750.
Price Target Update
Analysts polled by Thomson Reuters have set a consensus target price of $54.300 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.